ReviewMolecular and clinical oncology2025

Taking the 'low' into consideration: Discussions on redefining HER2 status in breast cancer (Review).

Alexandros Georgiou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.